Skip to main content
    N

    NeoGenomics Inc (NEO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $15.25
    -0.16 (-1.04%)

    Market Cap: $1.99B

    Last updated: Nov 17, 2026 at 4:26 PM ET

    NeoGenomics Inc (NEO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    NeoGenomics (NEO) has a market cap of $1.99B and an enterprise value of $2.24B. Its trailing P/E is 217.9x.

    Total Valuation

    Enterprise value is 12.11% above the market cap, as debt exceeds cash.

    Market Cap$1.99B
    Enterprise Value$2.24B
    Latest price (Nov 17, 2026)$15.25

    Key Dates

    The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 15, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.72% in the quarter ended Sep 30, 2026 and grew 0.64% a year over 2 years.

    Shares Outstanding128.59M
    Shares Change (YoY)+0.52%
    Shares Change (QoQ)-1.72%
    Share Count Growth (2Y CAGR)+0.64%

    Valuation Ratios

    Sales and book value multiples are 2.5x and 2.4x. Its year-end P/E ranged from 53.6x to 384.6x from 2016 to 2020.

    P/E Ratio217.9x
    Forward P/E74.2x
    P/S Ratio2.5x
    Forward P/S2.5x
    P/B Ratio2.4x
    P/TBV Ratio150.7x
    P/OCF Ratio465.9x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 68.2x EBITDA.

    EV / Sales2.8x
    EV / EBITDA68.2x

    Price Statistics

    The stock is up 47.49% over 52 weeks and trades 12.66% below its 50-day average.

    Beta (1Y)1.15
    52-Week Change+47.49%
    1-Month Change-7.13%
    3-Month Change-8.44%
    6-Month Change+81.76%
    5-Year Change-62.22%
    10-Year Change+115.63%
    Total Return (1Y)+47.49%
    Total Return (3Y CAGR)-7.72%
    Total Return (5Y CAGR)-17.13%
    Return vs SPY (1Y)+34.93%
    Max Drawdown (1Y)-45.61%
    Max Drawdown (3Y)-76.65%
    Sharpe Ratio (1Y)0.72
    Correlation with SPY (1Y)0.30
    50-Day Average$17.46
    200-Day Average$13.02
    52-Week Range$7.07 to $20.15
    RSI (14 Days)36.9
    Average Volume (20 Days)1.75M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.53x current liabilities, and total debt is 0.48x shareholder equity.

    Current Ratio3.53x
    Quick Ratio3.31x
    Debt / Equity0.48x
    Debt / EBITDA11.80x
    Interest Coverage-10.15x

    Returns and Efficiency

    Return on invested capital is -2.49% over the last 12 months, against a 5-year average of -5.58%.

    Return on Equity (ROE)-4.03%
    Return on Assets (ROA)-2.35%
    Return on Invested Capital (ROIC)-2.49%
    Return on Capital Employed (ROCE)-2.61%
    ROE (5Y Average)-9.24%
    ROA (5Y Average)-5.34%
    ROIC (5Y Average)-5.58%
    Asset Turnover0.57x
    Inventory Turnover16.82x
    Receivables Turnover4.05x
    Cash Conversion Cycle57 days

    Scores

    NEO has an Altman Z-Score of 2.33, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score2.33
    Altman Z ZoneGrey
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $787.75M over the last 12 months is up 11.08% from the 12 months before.

    Revenue$787.75M
    Revenue Growth (YoY)+11.08%
    Gross Profit$345.04M
    Operating Income-$47.09M
    Pretax Income-$36.18M
    Net Income-$32.30M
    EBITDA$32.27M
    EBIT-$32.93M
    Reported EPS (TTM)$0.07

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 58.02% of the $1.38B in total assets.

    Cash and Equivalents$139.28M
    Total Debt$380.69M
    Net Debt$241.41M
    Working Capital$293.91M
    Shareholder Equity$800.64M
    Tangible Book Value$13.02M
    Total Assets$1.38B
    Total Liabilities$576.28M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $32.86M of capital spending, operating cash flow left -$28.58M of free cash flow.

    Operating Cash Flow$4.28M
    Capital Expenditures$32.86M
    Free Cash Flow-$28.58M
    FCF Per Share-$0.22
    Depreciation and Amortization$65.21M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -5.98%, against a 5-year average of -19.34%.

    Gross Margin43.80%
    Operating Margin-5.98%
    Pretax Margin-4.59%
    Net Margin-4.10%
    EBITDA Margin4.10%
    EBIT Margin-4.18%
    FCF Margin-3.63%
    Gross Margin (5Y Average)39.92%
    Operating Margin (5Y Average)-19.34%
    Net Margin (5Y Average)-14.33%

    Growth

    Revenue grew 12.58% a year over 3 years.

    Revenue Growth (3Y CAGR)+12.58%
    Revenue Growth (5Y CAGR)+10.35%

    Revenue and profit by year

    Dividends and Yields

    NEO does not pay a dividend. Its free cash flow yield is -1.46%.

    Earnings Yield0.46%
    FCF Yield-1.46%
    Shareholder Yield0.00%

    Peer Position

    Against 5 similar companies, NEO has the highest P/E.

    P/E Ratio217.9x vs 20.5x median
    P/S Ratio2.5x vs 3.5x median
    ROIC-2.49% vs -1.31% median
    Revenue Growth (Trailing 4 Quarters, YoY)+11.08% vs +13.33% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.01% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+9.01%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NEO

    What is NEO's market cap?

    NeoGenomics has a market cap of $1.99B. Its enterprise value, which adds debt and subtracts cash, is $2.24B.

    What is NEO's P/E ratio?

    NeoGenomics has a trailing P/E ratio of 217.9x and a forward P/E of 74.2x.

    How many shares of NEO are outstanding?

    NeoGenomics has 128.59M shares outstanding. The count is up 0.52% from a year earlier.

    Does NEO pay a dividend?

    No. NeoGenomics does not pay a dividend.

    How much debt does NEO have?

    NeoGenomics has $380.69M of total debt and $139.28M of cash and equivalents, a net debt position of $241.41M.